Musculoskeletal Diseases

All Conditions

Skin and Connective Tissue Diseases

Neoplasms

Nervous System Diseases

Joint Diseases

Connective Tissue Diseases

Contracture

Fibroma

Dupuytren Contracture

Neoplasms by Histologic Type

Neoplasms, Connective and Soft Tissue

Neoplasms, Connective Tissue

Neoplasms, Fibrous Tissue

Muscular Diseases

Anti-Inflammatory Agents

Antineoplastic Agents

All Drugs and Chemicals

Antiemetics

Neuroprotective Agents

Gastrointestinal Agents

Prednisolone

Methylprednisolone

Methylprednisolone Acetate

Methylprednisolone Hemisuccinate

Prednisolone acetate

Prednisolone hemisuccinate

Prednisolone phosphate

Percutaneous needle fasciotomy with corticosteroid injection

Percutaneous needle fasciotomy with saline injection

Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre

Percutaneous needle fasciotomy

Corticosteroid injection

Saline injection

Laura H Matthiesen, MS, PhD-student

Jeppe Lange, MD, PhD

Laura H Matthiesen, PhD Student

Comparing percutaneous needle fasciotomy +/- corticosteroid injection for Dupuytren's contracture affecting metacarpophalangeal joints. A clinician-initiated, multicenter, randomized controlled trial.

Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture

Percutaneous Needle Fasciotomy (PNF) +/- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial

Recurrence is defined as 20 degrees or more passive extension deficit in metacarpophalangeal joint from baseline

Regionshospitalet Silkeborg

Medical Student, PhD Student

Symptoms and General Pathology

Immune System Diseases

Arthritis

Necrosis

Arthritis, Rheumatoid

Rheumatic Diseases

Collagen Diseases

Autoimmune Diseases

Antirheumatic Agents

Adalimumab

Tumor Necrosis Factor Inhibitors

Open-label, one arm only. All patients receiving active drug according to recommendations (adalimumab (Humira) 40 mg subcutaneously every other week).

Adalimumab (Humira) 40 mg subcutaneously every other week

Adalimumab (Humira)

Mikkel Østergaard, Professor

Uffe Møller Døhn, M.D

Studies on tumor necrosis factor alpha antagonist (anti-TNF) therapy in rheumatoid arthritis (RA) patients have found that erosive damage may "heal" in some RA patients treated with anti-TNF. Repeated examinations of adalimumab (Humira) treated RA patients, using computed tomography (CT), magnetic resonance imaging (MRI), ultrasonography (US) and radiography will allow detailed assessment of the extent of bone repair/healing during adalimumab (Humira) therapy.

Studies on tumor necrosis factor alpha antagonist (anti-TNF) therapy in rheumatoid arthritis (RA) patients have found that radiographic erosions scores decreased in some patients. This suggests that erosive damage may "heal" in some RA patients treated with anti-TNF. However, it is not clarified whether the reduced scores are caused by technical issues as observer variation and image acquisition differences. Furthermore, radiography of erosions is a 2D representation of a 3D pathology and therefore not ideal for visualizing healing, if present. Verification of erosion healing under anti-TNF therapy with adalimumab (Humira) by optimal imaging methods, would markedly influence our perception of the effect and potential of adalimumab (Humira) for modifying structural joint damage in RA. Magnetic Resonance Imaging (MRI), allowing high-resolution 3D visualization of bone damage as well as the inflammatory activity in the bone (bone marrow edema/osteitis), is more sensitive for visualization of bone erosions than radiography. Computed Tomography (CT) is a 3D radiographic imaging technique, which is not suited for assessment of inflammation, but can be considered a reference method for assessment of bone damage, due to its direct 3D visualization of calcified tissue. Internationally recommended MRI scoring systems as well as methods for estimation of erosion volumes have been developed, with participation by our research group. Ultrasonography (US), even though less validated, is more sensitive than radiography and comparable to MRI in detecting bone erosions in RA joints. Additionally, US provides visualisation of soft tissue changes and synovitis, using gray-scale and Doppler US.

Repeated MRI, CT, US and radiographic examinations of RA joints with mild to moderate radiographic damage under adalimumab (Humira) therapy will allow detailed assessment of the extent of bone repair/healing during adalimumab (Humira) therapy.

Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?

Can Bone Erosions Heal in Adalimumab (Humira) Treated Rheumatoid Arthritis Patients. An Imaging Study Using Computed Tomography and Magnetic Resonance Imaging.

Abbott

Hvidovre University Hospital

Mikkel Østergaard

Heart and Blood Diseases

Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

Diseases and Abnormalities at or Before Birth

Infections

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Coronary Artery Disease

Stroke

Diabetes Mellitus

Diabetic Foot

Lung Diseases

Ear Diseases

Congenital Abnormalities

Pneumonia

Coronary Disease

Myocardial Ischemia

Lung Diseases, Interstitial

Ulcer

Foot Ulcer

Kidney Calculi

Calculi

Nephrolithiasis

Hyperaldosteronism

Adrenocortical Adenoma

Labyrinth Diseases

Labyrinthitis

Intracranial Arteriovenous Malformations

Arteriovenous Malformations

Adenoma

Ischemia

Heart Diseases

Arteriosclerosis

Arterial Occlusive Diseases

Vascular Diseases

Respiratory Tract Diseases

Diabetic Angiopathies

Leg Ulcer

Skin Ulcer

Skin Diseases

Diabetes Complications

Endocrine System Diseases

Diabetic Neuropathies

Foot Diseases

Kidney Diseases

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urolithiasis

Urinary Calculi

Male Urogenital Diseases

Pathological Conditions, Anatomical

Vascular Malformations

Cardiovascular Abnormalities

Adrenocortical Hyperfunction

Adrenal Gland Diseases

Otorhinolaryngologic Diseases

Adrenal Cortex Neoplasms

Adrenal Gland Neoplasms

Endocrine Gland Neoplasms

Adrenal Cortex Diseases

Otitis

Cerebrovascular Disorders

Brain Diseases

Central Nervous System Diseases

Central Nervous System Vascular Malformations

Nervous System Malformations

Intracranial Arterial Diseases

Adenoma of the Adrenal Gland

Intracranial Arteriovenous Malformation

Hyperadrenalism

Micronutrients

Zinc

Comparative intra-patients (each patient will have both types of scanner imaging done), clinical superiority study, evaluating the imaging performances (e.g. image quality and radiation dose) of SPCCT and standard DECT for several body regions/anatomical structures.

For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition:

* Tube potential 120 kVp;
* Tube current time product of 150 mAs;
* Gantry revolution time 0.33 s;
* Automatic exposure control (angular and longitudinal) combined xyz-axis;
* Beam collimation geometry 64 x 0.625 mm - scan field-of-view - 22 cm;

Spectral Photon Counting Computed Tomography (SPCCT)

The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters:

* Base platform : iCT scanner
* Tube Voltage (kVp) : 120, capability for imaging at 80 and 100 kVp
* Tube current (mA) : 10 - 300
* Spatial Resolution : \> 30 lp/cm, ≤ 250 µm
* Z-coverage isocenter (mm) : 20 mm
* FOV (mm) : 500
* Minimum rotation time : 0.33 s/rotation
* Acquisition modes : Axial, Helical, Step \& Shoot

DECT (Dual Energy CT)

Philippe DOUEK, Pr

Adeline MANSUY

This pilot study wants to determine to which extent SPCCT allows obtaining images with improved quality and diagnostic confidence when compared to standard Dual Energy CT (DECT), both with and without contrast agent injection.

Depending on the anatomical structures/organs to be visualized during CT examinations, different scanning protocols are performed with quite variable ionizing radiation doses. Therefore, in order to obtain the most extensive and representative results of the improvement in image quality between SPCCT and DECT that will be performed CT imaging on several body regions and structures, including diabetic foot, diabetic calcium coronary scoring, adrenal glands, coronary arteries, lung parenchyma, kidney stones, inner ear, brain and joints, earl/temporal bone, colorectal carcinosis.

Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)

A single four-point scale will be used (1: unacceptable, 2: usable under limited conditions, 3: probably acceptable, 4: fully acceptable) based on the European guidelines on quality criteria for computed tomography

The diagnostic confidence grade will be calculated on a four-point scale (1: insufficient, 2: poor, 3: average, 4: good).

It will be calculated on a five-point scale (1: poor, 2: fair, 3: average, 4: good, 5: excellent) for each following criterion: noise, artifacts and sharpness.

To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures.

The CTDI is an estimation of the dose delivered to the organs for each acquired section that is based on acquisition parameters of a water phantom with a 32 cm diameter. The value is expressed in milligray (mGy).

To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures.

The DLP is obtained as follows: CTDI \* length of body explored = value in mGy.cm.

To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures.

The equivalent dose is obtained by multiplying the DLP to the specific organ conversion factor.

The noise by selecting regions of interest (ROI) will calculated.

The density (HU) by selecting regions of interest (ROI) will calculated.

The contrast-to-noise ratio (CNR) by selecting regions of interest (ROI) will calculated.

Depiction of anatomical structures of interest will be graded on a four-point scale (1: visualization just possible, 2: unclear borders but different structures already visible, 3: very good visualization, well-defined anatomy, 4: perfect delineation of anatomy).

An average radiation dose delivered to the patients for each clinical application will be calculated.

Statistical comparison between SPCCT and DECT will be performed over all images and anatomical structures globally and also for each clinical application of interest.

Hospices Civils de Lyon

Wounds and Injuries

Synovitis

Giant Cell Tumors

Giant Cell Tumor of Tendon Sheath

Synovitis, Pigmented Villonodular

Tendinopathy

Pigmented Villonodular Synovitis

Part 1: Open-label, sequential PLX73086 dose escalation in approximately 36 solid tumors subjects.

Part 2: Extension cohort at the recommended phase 2 dose (RP2D) of PLX73086 in approximately 30 subjects with histologically confirmed, unresectable, locally advanced or refractory TGCT (including metastatic disease).

PLX73086

The purpose of this research study is to evaluate safety, pharmacokinetics and preliminary efficacy of the investigational drug PLX73086 in subjects with solid tumors including subjects with locally advanced or refractory tenosynovial giant cell tumor (TGCT).

A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor

A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)

Plexxikon

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture	NCT05440240	Dupuytren Contr... Dupuytren's Dis... Contracture Joint Diseases Musculoskeletal... Fibroma Neoplasm, Fibro... Neoplasms, Conn... Neoplasms, Conn... Neoplasms by Hi... Neoplasms Connective Tiss...	Percutaneous ne... Corticosteroid ... Saline injectio...	45 Years - 99 Years	Regionshospitalet Silkeborg
Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?	NCT00696059	Rheumatoid Arth... Arthritis Joint Diseases	Adalimumab (Hum...	18 Years - 90 Years	Hvidovre University Hospital
Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)	NCT04328181	Diabetic Foot U... Coronary Artery... Parenchymatous;... Kidney Stone Inner Ear Disea... Brain Stroke Joint Diseases Diabetes Adrenal Inciden... Hyperaldosteron... Macroadenoma Interstitial Lu... Intracranial Ar...	Spectral Photon... DECT (Dual Ener...	18 Years -	Hospices Civils de Lyon
A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor	NCT02673736	Solid Tumors Tenosynovial Gi... Synovitis, Pigm...	PLX73086	18 Years -	Plexxikon
Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture	NCT05440240	Dupuytren Contr... Dupuytren's Dis... Contracture Joint Diseases Musculoskeletal... Fibroma Neoplasm, Fibro... Neoplasms, Conn... Neoplasms, Conn... Neoplasms by Hi... Neoplasms Connective Tiss...	Percutaneous ne... Corticosteroid ... Saline injectio...	45 Years - 99 Years	Regionshospitalet Silkeborg
A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor	NCT02673736	Solid Tumors Tenosynovial Gi... Synovitis, Pigm...	PLX73086	18 Years -	Plexxikon
Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture	NCT05440240	Dupuytren Contr... Dupuytren's Dis... Contracture Joint Diseases Musculoskeletal... Fibroma Neoplasm, Fibro... Neoplasms, Conn... Neoplasms, Conn... Neoplasms by Hi... Neoplasms Connective Tiss...	Percutaneous ne... Corticosteroid ... Saline injectio...	45 Years - 99 Years	Regionshospitalet Silkeborg

Spots Global Cancer Trial Database for joint diseases